NASDAQ OMX

Rapid7 Launches New Channel Partner Program

23.5.2017 22:05 | NASDAQ OMX

Dela
  • Newly expanded sales leadership team strengthens global channel partner program
  • Rapid7 has selected strategic partners to deliver expanded solutions and services leveraging the Rapid7 Insight platform

BOSTON, May 23, 2017 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ:RPD), a leading provider of analytics solutions for security and IT operations, today announced its next generation partner program: Rapid7 PACT, Partnering with Accountability, Consistency, and Transparency. Built to inspire Rapid7 partners to grow with the Company, the new program was created to enhance Rapid7's expanding portfolio of products and services, while better defining parameters for ongoing mutual success.

"We believe our partners are a key element to our next phase of growth. The introduction of PACT is designed to strengthen relationships with partners who are prepared to meet customer needs in a changing IT and security landscape," said Andrew Burton, COO of Rapid7. "We are incredibly excited to demonstrate a renewed commitment to our channel community through dedicated support programs, an industry-leading platform, and differentiated benefits."

Rapid7 PACT puts an increased focus on enabling partners to deliver the Company's expanded solutions and professional services at scale, with virtual training and certification programs, interactive reporting and analytics, and readily available success metrics. Setting it apart from more traditional channel programs, Rapid7 will equip its channel partners to directly perform professional, deployment, and training services, helping to drive immediate value. The new program structure also provides partners with a significant opportunity for growth by rewarding increased levels of partnership and investment.

"Our clients face new cyber security threats and operational IT challenges every day. At Vandis, we're focused on arming our clients with industry-leading solutions that give them the answers they need to act fast when an incident does occur - regardless of what new situations they encounter," said Andy Segal, CEO, Vandis, Inc. "Rapid7's analytics-driven, platform approach gives our clients live visibility into what's happening across their IT environments, from their endpoints to the cloud. That type of confidence is invaluable. We are thrilled to deepen our partnership with Rapid7 and applaud their expanded commitment to channel partners."

Rapid7 works with resellers and distributors to meet the needs of its customers in more than 100 countries around the globe. For regions outside the US where Rapid7 engages with local distributors, dedicated Rapid7 PACT guidelines will be established and rolled out over the course of H2 2017.

The Power of Insight: The Rapid7 Platform

The Rapid7 Insight platform makes it possible for security and IT professionals to share data, research findings, and analytic-processing resources, significantly reducing the overall total cost of ownership inherent with on-premise, analytics-driven solutions. Processing more than 50 billion events and monitoring millions of assets daily, the Insight platform is the first to unify solutions for vulnerability management, user behavior analytics (UBA), SIEM, IT log analytics, and application security.

"Today's security and IT professionals need live analytics and comprehensive visibility into their environments in order to understand and manage risk, detect threats, and monitor operations productivity," said Corey Thomas, president and CEO of Rapid7. "We're focused on building partner relationships that understand these needs, are committed to our vision, and are dedicated to helping security and IT teams keep up with today's shifting threat landscape."

The cloud-based platform also automatically scales to meet the needs of users, helping to solve challenges presented by rapid data growth for both security and IT. This unified approach to data and resource sharing is core to the philosophy behind Rapid7's mission to help security and IT professionals manage their environments through simplified solutions.

For more information or to see a list of existing Rapid7 partners, please visit: https://www.rapid7.com/partners/sales-partners

About Rapid7
Rapid7 (NASDAQ:RPD) is trusted by IT and security professionals around the world to manage risk, simplify modern IT complexity, and drive innovation. Rapid7 analytics transform today's vast amounts of security and IT data into the answers needed to securely develop and operate sophisticated IT networks and applications. Rapid7 research, technology, and services drive vulnerability management, penetration testing, application security, incident detection and response, and log management for more than 6,300 organizations across more than 120 countries, including 39% of the Fortune 1000. To learn more about Rapid7 or join our threat research, visit www.rapid7.com

Press contact:
Rachel E. Adam
Rapid7, Senior PR Manager
press@rapid7.com
(857) 990-4136

Investors:
Jeff Bray, CFA
Rapid7, Vice President, Investor Relations
investors@rapid7.com
(857) 990-4074

 

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Rapid7 via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressmeddelande

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressmeddelande

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressmeddelande

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressmeddelande

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38Pressmeddelande

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressmeddelande

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum